New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 18, 2014
09:00 EDTACRXAcelRx attractive ahead of Zalviso PDUFA, says Roth Capital
Roth Capital believes that AcelRx's Zalviso has the potential to replace IV PCA across many U.S. hospitals for treating patients with moderate-to-severe pain. The firm thinks the drug is likely to be approved next week and views the stock's recent weakness as a buying opportunity.
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
07:19 EDTACRXAcelRx's Zalviso for abdominal pain shows positive Phase 3 results
Subscribe for More Information
October 16, 2014
07:02 EDTACRXAcelRx updates patent portfolio for Zalviso and platform technologies
Subscribe for More Information
October 9, 2014
10:27 EDTACRXAcelRx management to meet with Guggenheim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use